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This Month in the Journal
This month in the Journal, Norman Arnheim, Peter Cala-
brese, and Magnus Nordborg contribute a review article
on recombination in the human genome. They discuss the
importance of deciphering recombination patterns,which
may or may not fully explain blocks of linkage dis-
equilibrium, the factors governing resolution and ac-
curacy in recombination maps, and the techniques that
can be used to study recombination. Only with a greater
understanding of the recombination patterns in a variety
of regions will we understand the factors underlying re-
combination rates.
Genome Scan Meta-analysis: Methods, by Levinson et
al. (p. 17), Schizophrenia Genome Scan Meta-analysis,
by Lewis et al. (p. 34), and Bipolar Disorder Genome
Scan Meta-analysis, by Segurado et al. (p. 49)
Three papers in this issue discuss genome scan meta-
analysis (GSMA) and its unbiased application to complex
disorders. This method has the advantage that raw data
and the precise positional relationships of markers be-
tween the original studies need not be known because it
places markers within 30-cM bins that are then ranked
by linkage scores. In the paper by Levinson et al., simula-
tion studies are used to determine the power of GSMA
to detect linkage. These simulations also identify thresh-
olds of signiﬁcance for application to the actual meta-
analyses. GSMA is as powerful as, if not more powerful
than, nonparametric linkage methods, partly because the
use of bins requires a more modest correction for mul-
tiple testing.
Lewis et al. apply the GSMA method to 20 schizo-
phrenia linkage scans in which at least 30 affected case
subjects with schizophrenia or schizoaffective disorder
were genotyped with markers at 30-cM or ﬁner density.
The overall analysis meets three aggregate criteria for
linkage, which means that more bins achieved evidence
of linkage than expected by chance and suggests that
multiple loci are linked to schizophrenia. The only bin
that achieves genomewide signiﬁcance after correction
for multiple testing corresponds to chromosome 2p12–
q22.1, a region that previously was not considered to
be a top candidate region for schizophrenia.
Segurado et al. study bipolar disorder using the
GSMAmethod. They include all known bipolar genome
scans with at least 20 affected case subjects. Because
major mood disorders coaggregate in families of people
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with bipolar disorder, they select two primary phenotypic
models for use in their analysis. The ﬁrst includes as
affected cases of either BP-I or BP-I and schizoaffective-
bipolar disorder (SAB). The second includes BP-I,
SAB, and BP-II. A secondary analysis with broader dis-
ease models was also performed. Although promising
results are identiﬁed in several regions, no bins reach a
genomewide level of signiﬁcance in the analysis. This
may be due to the much smaller number of pedigrees
with bipolar disorder who were analyzed, compared
with the schizophrenia study, which decreases the power
of the analysis. Simulation studies do suggest the bins
that are most likely to be linked to bipolar disorder. The
authors plan to update this analysis as additional ge-
nome scans are completed.
Selecting SNPs for Association Analyses, by Meng et
al. (p. 115)
SNP-selection strategies that maintain the majority of
information in a genetic region while limiting the amount
of genotyping required will be valuable for association
studies. Meng et al. propose a unique SNP-selection
method that does not rely on the deﬁnition of haplotype
blocks. In fact, their method can use genotype data rather
than haplotype data. As an added beneﬁt, a sliding-win-
dow approach allows them to apply the method to large
genetic regions. The goal of their method is to select a
subset of SNPs that preserves local haplotype frequen-
cies, thus maintaining haplotype information after
marker selection. They compare their method with an
extension of the htSNP-diversity method originally pro-
posed by Clayton (see Meng et al. references). Simu-
lations allow them to suggest appropriate sliding-win-
dow and sample sizes for use with the methods, and an
application to real data from chromosomes 12 and 22
shows that the majority of haplotype information can
be maintained while achieving substantial reductions in
the number of SNPs that need to be analyzed. Marker
selection has a negligible impact on the results of an
association study that makes use of the chromosome 22
data, although the authors caution that this may not be
true in every case. Meng et al. propose this method as
a way to prioritize markers for a ﬁrst genotyping screen,
which can then be followed up with additional markers
in the regions of interest.
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Allelic Variation in COMT Expression, by Bray et al.
(p. 152)
Recent work has found an association between schizo-
phrenia and the gene encoding catechol-O-methyltrans-
ferase (COMT). Schizophrenia is believed by many to be
the result of hyperdopaminergic function, and COMT
is involved in the metabolism of released dopamine. Bray
et al. therefore postulate that COMT genotypes that are
overrepresented in schizophrenics might be associated
with an altered level of COMT expression. To determine
whether this is true, they quantitate allele-speciﬁc ex-
pression of COMT using mRNA from human brain. In-
deed, they do ﬁnd allele-speciﬁc differences in COMT
expression, including reduced expression of a haplotype
that includes the functional Val/Met COMT polymor-
phism and is associated with schizophrenia. Lower rela-
tive expression of the schizophrenia-associated allelewas
also observed for the SNP that was most strongly as-
sociated with schizophrenia in the study of Shifman et
al. (see Bray et al. references). Although Bray et al. have
not demonstrated that these ﬁndings translate to protein
differences, the results do suggest a nice model wherein
reduced expression of COMT increases susceptibility to
schizophrenia due to increases in dopamine levels.
Unique 3′-End Lesions Cause Fabry Disease, by
Yasuda et al. (p. 162)
The gene encoding a-galactosidase A (a-Gal A) is un-
usual in that it lacks a 3′ UTR and has its polyadeny-
lation signal in the coding sequence. Yasuda et al. report
two individuals with Fabry disease, which is caused by
a deﬁciency of a-Gal A, who have mutations altering 3′-
end formation of the encoded transcripts. Both muta-
tions are small deletions that cause frameshifts that affect
the termination codon. One of the mutations also affects
the polyadenylation signal. Although it has been pro-
posed that transcripts lacking a termination codon are
degraded by the “nonstop transcript decay” pathway,
the transcripts produced in these individuals are stable,
possibly due to the unique 3′ structure of this gene. Mul-
tiple transcripts are produced from each mutated gene,
some shorter than wild type and some longer, that seem
to result from alternative polyadenylation site usage and
aberrant cleavage site selection. Besides being novel Fa-
bry disease mutations, these deletions also provide fur-
ther information on 3′-end formation.
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